By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Swiss molecular diagnostics company Biocartis today announced it has completed its Series C equity financing round, raising €71 million ($96 million).
The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.
Diagnoplex received a boost toward commercializing its flagship PCR-based colon cancer blood test in the form of a "substantial" Series A financing extension by fellow Swiss biopharmaceutical conglomerate Debiopharm Group.
Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.
Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.